Search: (WFRF:(Koeberle Dieter)) lar1:(ki) >
Clinical benefit an...
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone : a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
- Article/chapterEnglish2008
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-102517
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-102517URI
-
https://doi.org/10.1200/JCO.2007.15.6240DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:117378859URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Conference Information: 9th World Congress of Psycho-Oncology London, ENGLAND, SEP 16-20, 2007
-
PURPOSE: To compare clinical benefit response (CBR) and quality of life (QOL) in patients receiving gemcitabine (Gem) plus capecitabine (Cap) versus single-agent Gem for advanced/metastatic pancreatic cancer. PATIENTS AND METHODS: Patients were randomly assigned to receive GemCap (oral Cap 650 mg/m(2) twice daily on days 1 through 14 plus Gem 1,000 mg/m(2) in a 30-minute infusion on days 1 and 8 every 3 weeks) or Gem (1,000 mg/m(2) in a 30-minute infusion weekly for 7 weeks, followed by a 1-week break, and then weekly for 3 weeks every 4 weeks) for 24 weeks or until progression. CBR criteria and QOL indicators were assessed over this period. CBR was defined as improvement from baseline for >or= 4 consecutive weeks in pain (pain intensity or analgesic consumption) and Karnofsky performance status, stability in one but improvement in the other, or stability in pain and performance status but improvement in weight. RESULTS: Of 319 patients, 19% treated with GemCap and 20% treated with Gem experienced a CBR, with a median duration of 9.5 and 6.5 weeks, respectively (P < .02); 54% of patients treated with GemCap and 60% treated with Gem had no CBR (remaining patients were not assessable). There was no treatment difference in QOL (n = 311). QOL indicators were improving under chemotherapy (P < .05). These changes differed by the time to failure, with a worsening 1 to 2 months before treatment failure (all P < .05). CONCLUSION: There is no indication of a difference in CBR or QOL between GemCap and Gem. Regardless of their initial condition, some patients experience an improvement in QOL on chemotherapy, followed by a worsening before treatment failure.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Dietrich, Daniel
(author)
-
Scheithauer, Werner
(author)
-
Gerber, Daniela
(author)
-
Bodoky, György
(author)
-
Ruhstaller, Thomas
(author)
-
Glimelius, BengtKarolinska Institutet,Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi(Swepub:uu)bengglim
(author)
-
Bajetta, Emilio
(author)
-
Schüller, Johannes
(author)
-
Saletti, Piercarlo
(author)
-
Bauer, Jean
(author)
-
Figer, Arie
(author)
-
Pestalozzi, Bernhard C.
(author)
-
Köhne, Claus-Henning
(author)
-
Mingrone, Walter
(author)
-
Stemmer, Salomon M.
(author)
-
Tàmas, Karin
(author)
-
Kornek, Gabriela V.
(author)
-
Koeberle, Dieter
(author)
-
Herrmann, Richard
(author)
-
Uppsala universitetInstitutionen för onkologi, radiologi och klinisk immunologi
(creator_code:org_t)
Related titles
-
In:Journal of Clinical Oncology26:22, s. 3695-37010732-183X1527-7755
Internet link
Find in a library
To the university's database
- By the author/editor
-
Bernhard, Jürg
-
Dietrich, Daniel
-
Scheithauer, Wer ...
-
Gerber, Daniela
-
Bodoky, György
-
Ruhstaller, Thom ...
-
show more...
-
Glimelius, Bengt
-
Bajetta, Emilio
-
Schüller, Johann ...
-
Saletti, Piercar ...
-
Bauer, Jean
-
Figer, Arie
-
Pestalozzi, Bern ...
-
Köhne, Claus-Hen ...
-
Mingrone, Walter
-
Stemmer, Salomon ...
-
Tàmas, Karin
-
Kornek, Gabriela ...
-
Koeberle, Dieter
-
Herrmann, Richar ...
-
show less...
- Articles in the publication
-
Journal of Clini ...
- By the university
-
Uppsala University
-
Karolinska Institutet